Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Income from Continuing Operations (2022 - 2024)

Summit Therapeutics (SMMT) has disclosed Income from Continuing Operations for 3 consecutive years, with 65623000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Income from Continuing Operations fell 81.23% year-over-year to 65623000.0, compared with a TTM value of 234684000.0 through Dec 2024, up 61.51%, and an annual FY2024 reading of 234684000.0, up 61.84% over the prior year.
  • Income from Continuing Operations was 65623000.0 for Q4 2024 at Summit Therapeutics, down from 60832000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 15794000.0 in Q2 2023 and bottomed at 537154000.0 in Q1 2023.
  • Average Income from Continuing Operations over 3 years is 95697111.11, with a median of 45510000.0 recorded in 2024.
  • Peak annual rise in Income from Continuing Operations hit 91.53% in 2024, while the deepest fall reached 297.11% in 2024.
  • Year by year, Income from Continuing Operations stood at 16940000.0 in 2022, then plummeted by 113.75% to 36210000.0 in 2023, then tumbled by 81.23% to 65623000.0 in 2024.
  • Business Quant data shows Income from Continuing Operations for SMMT at 65623000.0 in Q4 2024, 60832000.0 in Q3 2024, and 62719000.0 in Q2 2024.